Spotlight On Fremont: Biologics, Tailored By Mammalian Cell Culture Experts

Lilith Baczynski, Director of Boehringer Ingelheim BioXcellence™ USA, highlights how the Fremont, California facility supports the company’s global mammalian biologics manufacturing network. Situated in the San Francisco Bay Area’s biotech hub, the site combines advanced technology with large-scale capacity, enabling production from late‑stage clinical materials to full commercial supply. Its dual manufacturing trains and bioreactors ranging from 2,000 to 15,000 liters offer flexibility for multi‑product operations, allowing teams to respond quickly to partner needs.

Baczynski emphasizes that success extends beyond technical capabilities. Harmonized procedures across U.S., German, and Austrian sites ensure consistent quality and supply security, while deep expertise and collaborative partnerships help translate biologic innovation into market-ready therapies. Continuous innovation and operational agility keep the Fremont site aligned with evolving industry demands, driven by a commitment to quality and patient impact. Looking ahead, Baczynski envisions the U.S. operation becoming a partner of choice — recognized not just for manufacturing excellence, but for creative problem‑solving and the trust built with every collaboration.